Interview with Sabine Dandiguian, President, Janssen-Cilag France
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Pierre Fabre is the 2nd largest private French pharmaceutical group. Their positioning is what they refer to as the “from health to beauty” continuum of activities, being an extremely diverse healthcare company, with both a pharmaceuticals and a dermo-cosmetics division. In 2015 total company revenues reached 2.2 billion euros (2.49 billion USD) corresponding to a growth rate of five percent compared to the previous year, with the dermo‐cosmetics division representing 58 percent of sales. Pierre Fabre is becoming increasingly international, today 64 percent of revenues are generated beyond France. Their dermo-cosmetics business has been built upon pharmaceutical roots, providing Pierre Fabre with a clear competitive edge when compared to other pure cosmetic companies. When it comes to their pharmaceuticals business, Europe accounts for 75 percent of their turnover.
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
This interview was conducted with Jacques de Chilly and Theirry de Lumley of Aderly hereafter referred to as J.C. and T.L. respectively. Aderly was founded in 1974 in order to…
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
See our Cookie Privacy Policy Here
